

## ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE V1.1 EVALUATION FORM 2A

For therapies that are not likely to be curative with primary endpoint of OS

Name of study:			
Study medicine:		Indication:	
First author:		Year:	
		Journal:	
Name of evaluator:			

If median OS with the standard treatment >24 months

<b>GRADE 4</b>	HR $\leq 0.70$ <u>AND</u> gain $\geq 9$ months	<input type="radio"/>
	Increase in 5 year survival alone $\geq 10\%$	<input type="radio"/>
<b>GRADE 3</b>	HR $\leq 0.70$ <u>AND</u> gain $\geq 6$ -<9 months	<input type="radio"/>
<b>GRADE 2</b>	HR $\leq 0.70$ <u>AND</u> gain $\geq 4$ -<6 months	<input type="radio"/>
	HR $> 0.70$ - $0.75$ <u>AND</u> gain $\geq 4$ months	<input type="radio"/>
<b>GRADE 1</b>	HR $> 0.75$ <u>OR</u> gain <4 months	<input type="radio"/>

Mark with  $\checkmark$  if relevant

<b>Preliminary magnitude of clinical benefit grade (highest grade scored)</b>	<b>4</b>	<b>3</b>	<b>2</b>	<b>1</b>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Non-curative setting grading - 5 and 4 indicates a substantial magnitude of clinical benefit

## Quality of life/Grade 3-4 toxicities\* assessment

Does secondary endpoint QoL show improvement?

Are there statistically significantly less grade 3-4 toxicities impacting on daily well-being?\*

\*This does not include alopecia, myelosuppression, but rather chronic nausea, diarrhoea, fatigue, etc.

Mark with ✓ if relevant

## Adjustments

01. Upgrade 1 level if improved QoL and/or less grade 3-4 toxicities impacting daily well-being are shown
02. If there is a long term plateau in the survival curve, and OS advantage continues to be observed at 7 years, also score according to form 1 (treatments with curative potential) and present both scores i.e. A/4.

	5	4	3	2	1
<b>Final adjusted magnitude of clinical benefit grade</b>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Non-curative setting grading - 5 and 4 indicates a substantial magnitude of clinical benefit